Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q2
- 저널
- BMC CANCER19 · 2019
- 피인용
- Web of Science 18Scopus 17
- FWCI (Scopus)
- 0.48
- JCR IF
- JCR 2018 2.933
- ISSN
- 1471-2407
저자
- Chung, Young Shin제1저자Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University, College of Medicine, Seodaemun-gu Seoul, South Korea
- Park, Sang-Yoon교신저자Center for Uterine Cancer, Hospital, National Cancer Center, Ilnsandong-gu Goyang-si Gyeonggi-do, South Korea
- Lee, Jung-YunDepartment of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University, College of Medicine, Seodaemun-gu Seoul, South Korea
- Park, Jeong-YeolDepartment of Obstetrics and Gynecology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, South Korea
- Lee, Jeong-WonDepartment of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, South Korea
- Kim, Hee SeungDepartment of Obstetrics and Gynecology, Seoul National University, College of Medicine, Seoul, South Korea
- 서동수Department of Obstetrics and Gynecology, Pusan National University, School of Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea
- Kim, Yun HwanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Womans University, College of Medicine, Seoul, South Korea
- Lee, Jong-MinDepartment of Obstetrics and Gynecology, Kyung Hee University, Hospital at Gangdong, Kyung Hee University, College of Medicine, Seoul, South Korea
- Kim, MiseonDepartment of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University, College of Medicine, Seoul, South Korea
- Choi, Min ChulComprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea
- Shim, Seung-HyukDepartment of Obstetrics and Gynecology, Konkuk University, School of Medicine, Seoul, South Korea
- Lee, Keun HoDepartment of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, South Korea
- Song, TaejongDepartment of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, South Korea
- Hong, Jin HwaDepartment of Obstetrics and Gynecology, Guro Hospital, College of Medicine, Korea University, Seoul, South Korea
- Lee, Won MooDepartment of Obstetrics and Gynecology, Hanyang University, College of Medicine, Seoul, South Korea
- Lee, BanghyunDepartment of Obstetrics and Gynecology, Hallym University, Kangdong Sacred Heart Hospital, Seoul, South Korea
- Lee, In HoDepartment of Obstetrics and Gynecology, Cheil General Hospital, Women's Healthcare Center, Dankook University, College of Medicine, Seoul, South Korea
초록
Background Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer. Methods We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were evaluated according to histological subtypes. Results A total of 154 patients were included in this study, comprising 20 cases (13.0%) of mucinous adenocarcinoma, 31 cases (20.1%) of endometrioid adenocarcinoma, 28 (18.2%) cases of clear cell carcinoma, 29 (18.8%) cases of low-grade serous carcinoma and 12 cases (7.8%) of carcinosarcoma. Complete remission/partial remission after the third cycle of NAC was achieved in 100 (64.9%) patients and optimal debulking surgery (residual disease <= 1cm) at interval debulking surgery was achieved in 103 (66.9%) patients. The most common reason for performing NAC was high tumor burden (n=106, 68.8%). The median progression-free survival (PFS) was 14.3months and median overall survival (OS) was 52.9months. In multivariate analyses, mucinous and clear cell carcinoma were negative prognostic factors for both PFS (p=0.007 and p=0.017, respectively) and OS (p=0.002 and p=0.013, respectively). Conclusions In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.
키워드
Ovarian neoplasmsHistologic subtypeNeoadjuvant therapyNon-high grade serous carcinomaSurvivalPRIMARY SURGERYPROGNOSTIC-FACTORSSURVIVALTHERAPYMORTALITYHISTOLOGYWOMENTRIAL
식별자
- Scopus EID
- 2-s2.0-85064200183
- WoS UID
- 000464773900004



로그인
연구물 목록으로